FDA Grants Priority Review for Bezuclastinib Plus Sunitinib in GIST – Targeted Oncology
- FDA Grants Priority Review for Bezuclastinib Plus Sunitinib in GIST Targeted Oncology
- Cogent Biosciences Announces FDA Acceptance of New Drug Application (NDA) with Priority Review for Bezuclastinib in Combination with Sunitinib for Patients with GIST The Manila Times
- FDA Grants Priority Review to Bezuclastinib Plus Sunitinib for Previously Treated GIST OncLive
- Phase 3 PEAK Trial: Bezuclastinib Plus Sunitinib Improves PFS in Advanced GIST After Imatinib Consultant360
- Cogent Biosciences announces FDA acceptance of bezuclastinib NDA TipRanks
0
مشاهدة